Microsatellite instability in colorectal cancer.

Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III. Radiol Oncol (2011) 0.81

General aspects of colorectal cancer. ISRN Oncol (2012) 0.79

Comparison of survival of patients receiving laparoscopic and open radical resection for stage II colon cancer. Radiol Oncol (2011) 0.75

A genetic model for colorectal tumorigenesis. Cell (1990) 44.37

Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97

Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52

Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15

Genetic instability in colorectal cancers. Nature (1997) 12.51

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17

APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50

Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68

Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15

Mechanisms and biological effects of mismatch repair. Annu Rev Genet (1991) 7.86

DNA mismatch repair: functions and mechanisms. Chem Rev (2006) 6.03

Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 5.87

Colorectal cancer. Lancet (2005) 4.90

When checkpoints fail. Cell (1997) 4.21

Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res (2002) 3.39

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21

The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res (2008) 3.15

Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01

Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet (1994) 2.95

The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88

The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49

Emerging concepts in colorectal neoplasia. Gastroenterology (2002) 2.44

The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A (1999) 2.41

DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev (2008) 2.40

Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37

Epigenetic changes in colorectal cancer. Cancer Metastasis Rev (2004) 2.35

Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer (2010) 2.16

Genomic instability and colon cancer. Cancer Metastasis Rev (2004) 2.15

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer (2008) 2.08

Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res (2003) 1.92

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut (2005) 1.87

Concerted nonsyntenic allelic loss in human colorectal carcinoma. Science (1988) 1.81

Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer (2009) 1.74

Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol (2010) 1.62

The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology (2004) 1.62

The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res (1998) 1.39

5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology (2007) 1.39

Mismatch repair defects in human carcinogenesis. Hum Mol Genet (1996) 1.32

Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer (2002) 1.32

Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer (2000) 1.32

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol (2009) 1.26

The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol (2003) 1.24

Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev (2010) 1.19

High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer (2002) 1.15

Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res (1999) 1.10

Premalignancy of the mucosal polyp in the large intestine: II. Estimation of the periods required for malignant transformation of mucosal polyps. Dis Colon Rectum (1975) 1.10

High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res (2005) 1.04

Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res (2009) 1.03

Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol (2002) 1.03

Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res (2004) 1.00

Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (2010) 0.98

Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res (2007) 0.97

Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis (2004) 0.96

Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J Gastroenterol (2007) 0.96

Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelines. Radiol Oncol (2010) 0.95

Post-treatment surveillance in colorectal cancer. Radiol Oncol (2010) 0.94

The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94

Carcinogenesis. Missing mismatch repair. Nature (1994) 0.91

Prokaryotic DNA mismatch repair. Prog Nucleic Acid Res Mol Biol (2006) 0.88

Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention. Cancer Epidemiol Biomarkers Prev (2009) 0.86

The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am (2002) 0.84

[Pathological diagnosis for individualized therapy of colorectal cancer]. Pathologe (2010) 0.81

Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22

A "crossomics" study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One (2012) 0.86

Faecal immunochemical test-based colorectal cancer screening programme SVIT in Slovenia: pilot phase. Eur J Cancer Prev (2014) 0.79

Maintenance therapy of gastroesophageal reflux disease patients with omeprazole. Hepatogastroenterology (2009) 0.78

Fatal hemorrhage due to thrombosis and rupture of the portal vein and hepatic artery. Wien Klin Wochenschr (2009) 0.76

Results of the FIT-based National Colorectal Cancer Screening Program in Slovenia. J Clin Gastroenterol (2017) 0.76